As a leader in the regenerative medicine space, Organogenesis specializes in bioactive wound healing and soft tissue regeneration.

Our two main products are Apligraf®, which is FDA approved for the treatment of diabetic foot ulcers and venous leg ulcers, and Dermagraft®, which is FDA approved for the treatment of diabetic foot ulcers.

Chronic wounds are open wounds that for a variety of reasons fail to heal by the body’s own efforts. The three most common types of chronic wounds are diabetic foot ulcers, venous leg ulcers and pressure ulcers.

In the U.S. roughly three million patients suffer from chronic wounds, representing a burden to the healthcare system in excess of $10 billion.

Chronic wounds can lead to pain, diminished quality of life, impaired mobility, reduced productivity and in some cases, amputations. Good conventional wound care can often heal these wounds. However, roughly a third of these chronic wounds fail to heal and a more active approach to healing is needed.

Bio-active wound products are designed to enhance the body's natural healing process in these hard to heal patients.